Devita, Hellman, and Rosenberg's Cancer

LWBK1006-23 LWW-Govindan-Review December 12, 2011 19:10

Chapter 23•Gynecologic Cancers 307

Question 23.1.5. All of the following statements regarding the molecular genetics of ovarian

cancer are true, EXCEPT:

A. TP53 mutation is the most common mutation in patients with ovarian

carcinoma.

B. BAX overexpression is associated with better prognosis.

C. Vascular endothelial growth factor (VEGF) expression is associated

with better prognosis.

D. PTEN mutations are more common in endometrioid or mucinous

tumors.

Question 23.1.6. A 50-year-old woman presents with a pelvic mass. She is found to have a

tumor of low malignant potential. She undergoes a TAH/BSO and stag-

ing. She has no gross disease but has positive washings on final pathology

and one positive lymph node, making her disease stage IIIC. What is the

most appropriate therapy postoperatively?

A. Intraperitoneal cisplatin and intravenous (IV) taxane

B. IV platinum and a taxane

C. Hormonal therapy with tamoxifen or an aromatase inhibitor

D. No further therapy

Question 23.1.7. A 50-year-old woman was diagnosed with stage III ovarian cancer and

underwent primary resection followed by chemotherapy. She is asymp-

tomatic but has elevated CA-125. Imaging studies do not identify recur-

rent disease. Which of the following is the best treatment option?

A. Hormonal therapy

B. Platinum-based chemotherapy

C. Single agent doxorubicin

D. Single agent paclitaxel

Question 23.1.8. All of the following are founder mutations associated with individuals of

Ashkenazi descent, EXCEPT:

A. 185delAG

B. 5382insC

C. 617delT

D. 619delT

Question 23.1.9. A patient of Jewish heritage who has breast cancer, but no family history

of breast or ovarian cancer, has what chance of having a BRCA1 or

BRCA2 mutation?

A. 5%

B. 10%

C. 40%

D. 90%